Income Tax Expense (Benefit) in USD of Oncocyte Corp from Q1 2020 to Q3 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Oncocyte Corp quarterly/annual Income Tax Expense (Benefit) history and change rate from Q1 2020 to Q3 2025.
- Oncocyte Corp Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $0.000.
- Oncocyte Corp Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $0.000.
- Oncocyte Corp annual Income Tax Expense (Benefit) for 2024 was $0.000.
- Oncocyte Corp annual Income Tax Expense (Benefit) for 2023 was $0.000.
- Oncocyte Corp annual Income Tax Expense (Benefit) for 2021 was -$9.26M, a 639% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)